Bernd Giebel,
Group Leader, Institute for Transfusion Medicine,
University Hospital Duisburg-Essen
Bernd Giebel studied biology at the University zu Köln and received his PhD in 1996 at the Institute for Developmental Biology in Köln. He runs a lab at the Institute for Transfusion Medicine at the University Hospital Essen. Since 1999 he works with human hematopoietic stem cells and started in 2009 to explore the therapeutic potential of mesenchymal stem cell-derived extracellular vesicles. Together with collaboration partners the group demonstrated the therapeutic potential of prepared MSC-EVs in a human GvHD-patient and in different animal models. It is the current goal to optimize the MSC-EV production and characterization process to efficiently translate MSC-EVs into the clinics.
B Giebel is the president of the German Society of Extracellular Vesicles (GSEV) and a co-chair of the exosome working group of the International Society of Gene and Cell Therapy (ISCT) and an active member of the International Society of Extracellular Vesicles (ISEV). Furthermore, he is part of the scientific advisory board of two SME companies, Innovex Therapeutics and Mursla LTD. In 2021 he became a founding director of Exosla LTD.
Clinical Potential of MSC-EVs and Translational Challenges
Tuesday, 1 March 2022 at 14:30
Add to Calendar ▼2022-03-01 14:30:002022-03-01 15:30:00Europe/LondonClinical Potential of MSC-EVs and Translational ChallengesCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Small (exosome-sized) extracellular vesicles (sEVs) harvested from supernatants of human mesenchymal stromal cells (MSCs) exert therapeutic functions in various disease models. Furthermore, they have been successfully applied in a steroid-refractory Graft-versus-Host Disease patient and in a single centre, randomized, placebo-controlled phase II/III clinical pilot study on chronic kidney disease patients without revealing any site effects. Apparently one mode of action is their ability to modulate immune responses from the pro-inflammatory into the regulatory state. At the example of an ischemic stroke model, we demonstrate that systemically applied MSC-sEV preparations, considered as therapeutically active, attenuate stroke induced lymphopenia and neutrophil immigration into the lesion site and thus importantly contribute to the MSC-sEVs’ therapeutic effect. Notably, independent MSC-sEV preparations can differ in their immunomodulatory and therapeutic activity, with a proportion of them appearing therapeutically inactive. Thus, according to our understanding it is a challenging but essential task during the translation process into the clinics to develop appropriate potency assays allowing discrimination of therapeutically active and therapeutically inactive MSC-sEV preparations.
Add to Calendar ▼2022-03-01 00:00:002022-03-02 00:00:00Europe/LondonCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2022Circulating Biomarkers, Exosomes and Liquid Biopsy Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2022-03-01 14:30:002022-03-01 15:30:00Europe/LondonClinical Potential of MSC-EVs and Translational ChallengesCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
